JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Thromboangiitis obliterans (Buerger's disease) in women (a reevaluation).

Angiology 1993 July
Thromboangiitis obliterans (TAO) is an occlusive vascular disease traditionally known to be almost exclusive to young male smokers. The disease was considered to be extremely rare in women, seen only as isolated, novel case reports in the literature. In the past decade, however, a dramatic increase in the incidence of female TAO has been observed. In this paper the authors report 7 cases of clinically and angiographically verified female TAO. The world literature in regard to the diagnostic criteria, changing incidence, and etiology is reviewed. They conclude that the increased use of tobacco among young women in the past two to three decades is responsible for this dramatic change.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app